4prd - Revision history

OCA at 17:21, 20 September 2023

2023-09-20T17:21:14Z

← Older revision		Revision as of 17:21, 20 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Human_gammaherpesvirus_4 Human gammaherpesvirus 4]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PRD FirstGlance]. <br>		<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Human_gammaherpesvirus_4 Human gammaherpesvirus 4]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PRD FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene></td></tr>		</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 1.75Å</td></tr>
			<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [https://pdbe.org/4prd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [https://www.ebi.ac.uk/pdbsum/4prd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4prd ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [https://pdbe.org/4prd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [https://www.ebi.ac.uk/pdbsum/4prd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4prd ProSAT]</span></td></tr>
	</table>		</table>
Line 21:		Line 22:
	==See Also==		==See Also==
	*[[Beta-2 microglobulin 3D structures\|Beta-2 microglobulin 3D structures]]		*[[Beta-2 microglobulin 3D structures\|Beta-2 microglobulin 3D structures]]
			*[[MHC 3D structures\|MHC 3D structures]]
			*[[MHC I 3D structures\|MHC I 3D structures]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 07:26, 8 February 2023

2023-02-08T07:26:56Z

← Older revision		Revision as of 07:26, 8 February 2023
Line 1:		Line 1:

	==Crystal structure of a HLA-B*35:08-HPVG-D5==		==Crystal structure of a HLA-B*35:08-HPVG-D5==
	<StructureSection load='4prd' size='340' side='right' caption='[[4prd]], [[Resolution\|resolution]] 1.75Å' scene=''>		<StructureSection load='4prd' size='340' side='right'caption='[[4prd]], [[Resolution\|resolution]] 1.75Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/Human ~~Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4PRD FirstGlance]. <br>		<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Human_gammaherpesvirus_4 Human gammaherpesvirus 4]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4PRD FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>~~</td></tr>~~		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [https://pdbe.org/4prd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [https://www.ebi.ac.uk/pdbsum/4prd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4prd ProSAT]</span></td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [~~http~~://pdbe.org/4prd PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4prd PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=4prd ProSAT]</span></td></tr>
	</table>		</table>
	~~== Disease ==~~
	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
	== Function ==		== Function ==
	[~~[http~~://www.uniprot.org/uniprot/C5MK56_HUMAN C5MK56_HUMAN]] Involved in the presentation of foreign antigens to the immune system (By similarity).[SAAS:SAAS003006_004_004364] [[http://www.uniprot.org/uniprot/EBNA1_EBVG EBNA1_EBVG]] Plays an essential role in replication and partitioning of viral genomic DNA during latent viral infection. During this phase, the circular double-stranded viral DNA undergoes replication once per cell cycle and is efficiently partitioned to the daughter cells. EBNA1 activates the initiation of viral DNA replication through binding to specific sites in the viral latent origin of replication, oriP. Additionally, it governs the segregation of viral episomes by mediating their attachment to host cell metaphase chromosomes. Also activates the transcription of several viral latency genes. Finally, it can counteract the stabilization of host p53/TP53 by host USP7, thereby decreasing apoptosis and increasing host cell survival (By similarity). [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.		[https://www.uniprot.org/uniprot/C5MK56_HUMAN C5MK56_HUMAN] Involved in the presentation of foreign antigens to the immune system (By similarity).[SAAS:SAAS003006_004_004364]
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 22:		Line 18:
	</div>		</div>
	<div class="pdbe-citations 4prd" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4prd" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[Beta-2 microglobulin 3D structures\|Beta-2 microglobulin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
	[[Category: ~~Human]]~~		[[Category: Homo sapiens]]
	~~[[Category: Chih, L Yu]]~~		[[Category: Human gammaherpesvirus 4]]
	~~[[Category: Gras, S]]~~		[[Category: Large Structures]]
	~~[[Category: Rossjohn, J]]~~		[[Category: Gras S]]
	~~[[Category: Epstein-barr virus~~]]		[[Category: Rossjohn J]]
	[[Category: Human ~~leukocyte antigen class i~~]]		[[Category: Yu Chih L]]
	[[Category: ~~Immune system~~]]
	[[Category: ~~T cell receptor~~]]
	[[Category: ~~Viral escape~~]]
	[[Category: ~~Viral immunity~~]]

OCA at 08:44, 22 November 2017

2017-11-22T08:44:16Z

← Older revision		Revision as of 08:44, 22 November 2017
Line 22:		Line 22:
	</div>		</div>
	<div class="pdbe-citations 4prd" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 4prd" style="background-color:#fffaf0;"></div>

	~~==See Also==~~
	*[[Beta-2 microglobulin\|Beta-2 microglobulin]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 20:25, 11 August 2016

2016-08-11T20:25:02Z

← Older revision		Revision as of 20:25, 11 August 2016
Line 1:		Line 1:

	==Crystal structure of a HLA-B*35:08-HPVG-D5==		==Crystal structure of a HLA-B*35:08-HPVG-D5==
	<StructureSection load='4prd' size='340' side='right' caption='[[4prd]], [[Resolution\|resolution]] 1.75Å' scene=''>		<StructureSection load='4prd' size='340' side='right' caption='[[4prd]], [[Resolution\|resolution]] 1.75Å' scene=''>
Line 6:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [http://www.ebi.ac.uk/pdbsum/4prd PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [http://pdbe.org/4prd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [http://www.ebi.ac.uk/pdbsum/4prd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4prd ProSAT]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
			<div class="pdbe-citations 4prd" style="background-color:#fffaf0;"></div>

			==See Also==
			*[[Beta-2 microglobulin\|Beta-2 microglobulin]]
	== References ==		== References ==
	<references/>		<references/>

OCA at 09:07, 5 January 2015

2015-01-05T09:07:14Z

← Older revision		Revision as of 09:07, 5 January 2015
Line 3:		Line 3:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PRD FirstGlance]. <br>		<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PRD FirstGlance]. <br>
	</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene><br>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene></td></tr>
	<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>
	<tr><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [http://www.ebi.ac.uk/pdbsum/4prd PDBsum]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [http://www.ebi.ac.uk/pdbsum/4prd PDBsum]</span></td></tr>
	<table>		</table>
	== Disease ==		== Disease ==
	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>		[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
Line 25:		Line 25:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
	[[Category: Chih, L Yu.]]		[[Category: Chih, L Yu]]
	[[Category: Gras, S.]]		[[Category: Gras, S]]
	[[Category: Rossjohn, J.]]		[[Category: Rossjohn, J]]
	[[Category: Epstein-barr virus]]		[[Category: Epstein-barr virus]]
	[[Category: Human leukocyte antigen class i]]		[[Category: Human leukocyte antigen class i]]

OCA at 05:38, 18 June 2014

2014-06-18T05:38:32Z

← Older revision		Revision as of 05:38, 18 June 2014
Line 1:		Line 1:
	~~{{STRUCTURE_4prd\| PDB=4prd \| SCENE= }}~~		==Crystal structure of a HLA-B*35:08-HPVG-D5==
	===Crystal structure of a HLA-B*35:08-HPVG-D5===		<StructureSection load='4prd' size='340' side='right' caption='[[4prd]], [[Resolution\|resolution]] 1.75Å' scene=''>
			== Structural highlights ==
	==Disease==		<table><tr><td colspan='2'>[[4prd]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4PRD FirstGlance]. <br>
			</td></tr><tr><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene><br>
			<tr><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[2fyy\|2fyy]], [[3vm7\|3vm7]], [[4pr5\|4pr5]], [[4pra\|4pra]], [[4prb\|4prb]], [[4pre\|4pre]], [[4prh\|4prh]], [[4pri\|4pri]], [[4prn\|4prn]], [[4prp\|4prp]]</td></tr>
			<tr><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">HLA-B, HLAB ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), B2M, CDABP0092, HDCMA22P ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
			<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4prd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4prd OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4prd RCSB], [http://www.ebi.ac.uk/pdbsum/4prd PDBsum]</span></td></tr>
			<table>
			== Disease ==
	[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>		[[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP) [MIM:[http://omim.org/entry/241600 241600]]. Affected individuals show marked reduction in serum concentrations of immunoglobulin and albumin, probably due to rapid degradation.<ref>PMID:16549777</ref> Note=Beta-2-microglobulin may adopt the fibrillar configuration of amyloid in certain pathologic states. The capacity to assemble into amyloid fibrils is concentration dependent. Persistently high beta(2)-microglobulin serum levels lead to amyloidosis in patients on long-term hemodialysis.<ref>PMID:3532124</ref> <ref>PMID:1336137</ref> <ref>PMID:7554280</ref> <ref>PMID:4586824</ref> <ref>PMID:8084451</ref> <ref>PMID:12119416</ref> <ref>PMID:12796775</ref> <ref>PMID:16901902</ref> <ref>PMID:16491088</ref> <ref>PMID:17646174</ref> <ref>PMID:18835253</ref> <ref>PMID:18395224</ref> <ref>PMID:19284997</ref>
			== Function ==
	==Function==
	[[http://www.uniprot.org/uniprot/C5MK56_HUMAN C5MK56_HUMAN]] Involved in the presentation of foreign antigens to the immune system (By similarity).[SAAS:SAAS003006_004_004364] [[http://www.uniprot.org/uniprot/EBNA1_EBVG EBNA1_EBVG]] Plays an essential role in replication and partitioning of viral genomic DNA during latent viral infection. During this phase, the circular double-stranded viral DNA undergoes replication once per cell cycle and is efficiently partitioned to the daughter cells. EBNA1 activates the initiation of viral DNA replication through binding to specific sites in the viral latent origin of replication, oriP. Additionally, it governs the segregation of viral episomes by mediating their attachment to host cell metaphase chromosomes. Also activates the transcription of several viral latency genes. Finally, it can counteract the stabilization of host p53/TP53 by host USP7, thereby decreasing apoptosis and increasing host cell survival (By similarity). [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.		[[http://www.uniprot.org/uniprot/C5MK56_HUMAN C5MK56_HUMAN]] Involved in the presentation of foreign antigens to the immune system (By similarity).[SAAS:SAAS003006_004_004364] [[http://www.uniprot.org/uniprot/EBNA1_EBVG EBNA1_EBVG]] Plays an essential role in replication and partitioning of viral genomic DNA during latent viral infection. During this phase, the circular double-stranded viral DNA undergoes replication once per cell cycle and is efficiently partitioned to the daughter cells. EBNA1 activates the initiation of viral DNA replication through binding to specific sites in the viral latent origin of replication, oriP. Additionally, it governs the segregation of viral episomes by mediating their attachment to host cell metaphase chromosomes. Also activates the transcription of several viral latency genes. Finally, it can counteract the stabilization of host p53/TP53 by host USP7, thereby decreasing apoptosis and increasing host cell survival (By similarity). [[http://www.uniprot.org/uniprot/B2MG_HUMAN B2MG_HUMAN]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system.
			<div style="background-color:#fffaf0;">
			== Publication Abstract from PubMed ==
			Mutations within T cell epitopes represent a common mechanism of viral escape from the host protective immune response. The diverse T cell repertoire and the extensive human leukocyte antigen (HLA) polymorphism across populations is the evolutionary response to viral mutation. However, the molecular basis underpinning the interplay between HLA polymorphism, the T cell repertoire, and viral escape is unclear. Here we investigate the T cell response to a HLA-B35:01- and HLA-B35:08-restricted 407HPVGEADYFEY417 epitope from Epstein-Barr virus and naturally occurring variants at positions 4 and 5 thereof. Each viral variant differently impacted on the epitope's flexibility and conformation when bound to HLA-B35:08 or HLA-B35:01. We provide a molecular basis for understanding how the single residue polymorphism that discriminates between HLA-B35:01/08 profoundly impacts on T cell receptor recognition. Surprisingly, one viral variant (P5-Glu to P5-Asp) effectively changed restriction preference from HLA-B35:01 to HLA-B*35:08. Collectively, our study portrays the interplay between the T cell response, viral escape, and HLA polymorphism, whereby HLA polymorphism enables altered presentation of epitopes from different strains of Epstein-Barr virus.

	~~==About this Structure==~~		A Molecular Basis for the Interplay between T Cells, Viral Mutants, and Human Leukocyte Antigen Micropolymorphism.,Liu YC, Chen Z, Neller MA, Miles JJ, Purcell AW, McCluskey J, Burrows SR, Rossjohn J, Gras S J Biol Chem. 2014 Jun 13;289(24):16688-16698. Epub 2014 Apr 23. PMID:24759101<ref>PMID:24759101</ref>
	~~[[4prd]] is a 3 chain structure with sequence from [http://en~~.~~wikipedia.org/wiki/Human Human]~~. ~~Full crystallographic information is available from [http~~:~~//oca~~.~~weizmann~~.~~ac.il/oca-bin~~/~~ocashort?id=4PRD OCA].~~

	==~~Reference~~==		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	<references ~~group="xtra"~~/><~~references~~/>		</div>
			== References ==
			<references/>
			__TOC__
			</StructureSection>
	[[Category: Human]]		[[Category: Human]]
	[[Category: Chih, L Yu.]]		[[Category: Chih, L Yu.]]

OCA at 06:44, 23 April 2014

2014-04-23T06:44:09Z

← Older revision		Revision as of 06:44, 23 April 2014
Line 9:		Line 9:

	==About this Structure==		==About this Structure==
	[[4prd]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA].		[[4prd]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4PRD OCA].

	==Reference==		==Reference==
	<references group="xtra"/><references/>		<references group="xtra"/><references/>
			[[Category: Human]]
	[[Category: Chih, L Yu.]]		[[Category: Chih, L Yu.]]
	[[Category: Gras, S.]]		[[Category: Gras, S.]]

OCA at 10:11, 16 April 2014

2014-04-16T10:11:28Z

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+{{STRUCTURE_4prd|  PDB=4prd  |  SCENE=  }}
-The entry 4prd is ON HOLD  until Paper Publication
+==Disease==
-Authors: Yu Chih, L., Rossjohn, J., Gras, S.
+==Function==
-Description:
+==About this Structure==

OCA at 08:50, 26 March 2014

2014-03-26T08:50:27Z

← Older revision		Revision as of 08:50, 26 March 2014
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

	The entry 4prd is ON HOLD		The entry 4prd is ON HOLD until Paper Publication

	Authors: Yu Chih, L., Rossjohn, J., Gras, S.		Authors: Yu Chih, L., Rossjohn, J., Gras, S.

	Description:		Description:

OCA: Protected "4prd" [edit=sysop:move=sysop]

2014-03-12T12:36:52Z

Protected "4prd" [edit=sysop:move=sysop]

← Older revision	Revision as of 12:36, 12 March 2014
(No difference)